The median survival rate for chemotherapy-refractory IDH1-mutant cholangiocarcinoma patients receiving ivosidenib therapy is 2.7 months, while that of patients treated with a placebo is 1.4 months [43]. Here, IDH1 is linked to cholangiocarcinoma.